TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
10.70
-0.50 (-4.46%)
At close: Sep 12, 2025, 4:00 PM EDT
10.82
+0.12 (1.12%)
After-hours: Sep 12, 2025, 7:59 PM EDT

TransCode Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202019 - 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2020
Selling, General & Admin
55.957.158.43.40.44
Upgrade
Research & Development
9.659.7112.2610.232.750.28
Upgrade
Operating Expenses
14.6515.6619.4218.636.150.73
Upgrade
Operating Income
-14.65-15.66-19.42-18.63-6.15-0.73
Upgrade
Interest Expense
-0.01-0.03-0.06-0.03-0.1-0.39
Upgrade
Interest & Investment Income
000.010.0200
Upgrade
Currency Exchange Gain (Loss)
-0-0.06----
Upgrade
Other Non Operating Income (Expenses)
-9.93-1.010.921.08-0.59-1.22
Upgrade
EBT Excluding Unusual Items
-24.6-16.76-18.55-17.56-6.84-2.34
Upgrade
Gain (Loss) on Sale of Assets
00---0-
Upgrade
Pretax Income
-24.6-16.75-18.55-17.56-6.84-2.34
Upgrade
Net Income
-24.6-16.75-18.55-17.56-6.84-2.34
Upgrade
Net Income to Common
-24.6-16.75-18.55-17.56-6.84-2.34
Upgrade
Shares Outstanding (Basic)
00----
Upgrade
Shares Outstanding (Diluted)
00----
Upgrade
EPS (Basic)
-94.05-1317.42----
Upgrade
EPS (Diluted)
-94.05-1317.42----
Upgrade
Free Cash Flow
-14.36-13.36-18.11-15.86-5.52-0.49
Upgrade
Free Cash Flow Per Share
-54.92-1050.30----
Upgrade
EBITDA
-14.6-15.57-19.3-18.54-6.11-
Upgrade
D&A For EBITDA
0.050.090.120.10.04-
Upgrade
EBIT
-14.65-15.66-19.42-18.63-6.15-0.73
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q